50
Participants
Start Date
November 30, 2012
Primary Completion Date
March 31, 2014
Study Completion Date
March 31, 2014
Natalizumab discontinuation
Patients will be randomized to one of two groups: The Immediate Discontinuation Group (stop natalizumab immediately and continue with new DMT 1 month afterward) and the Taper-off Group (two additional infusions of natalizumab, one at 6 weeks and the next at 8 weeks following discontinuation. A new DMT will be initiated within 2 months of final natalizumab infusion).
Buffalo Neuroimaging Analysis Center, Buffalo
Jacobs Neurological Institute, Buffalo
University at Buffalo
OTHER